智通财经APP获悉，华西证券发布研报称，参考最新业绩预告，调整锅圈(02517)25-27年营业收入 76.46/90.83/108.20亿元的预测至78.03/91.83/108.2亿元，上调公司25-27年EPS 0.16/0.19/0.24元的预测至 0.16/0.20/0.25元，对应2026年1月30日4.26港元的估值分别为24/19/15倍，维持"买入"评级。 华西证券主要观点如下： 公司发布正面盈利报告 2025年预计实现收入77.5～78.5亿元，同比提升19.8%～21.3%；实现净利润4.43～4.63亿元，同比提升 83.7%～92%；核心经营利润4.5～4.7亿元，同比提升44.8%～51.2%。 大力开拓乡镇市场，推动收入快速增长公司 2025年持续大力开拓乡镇市场，乡镇市场低租金、高潜力的特点与锅圈"社区央厨"定位高度契合，成为 收入扩张的主要来源，25年公司全年收入预计同增19.8%～21.3%，规模达到77.5～78.5亿元。门店端来 看，截至2025年末锅圈门店数量达到11,566家，同比新增门店1,416家，其中Q4新增门店805家，规模扩 张速度符合公司下沉市场渗透节奏 ...

Core Viewpoint - The announcement details a new sales agreement between Invesco Great Wall Fund Management Co., Ltd. and Huaxi Securities Co., Ltd. for the distribution of certain funds starting from February 5, 2026 [1]. Group 1: Applicable Funds - The announcement specifies that certain funds managed by Invesco Great Wall will be available for sale through Huaxi Securities [1]. Group 2: Sales Institution Information - The sales institution is Huaxi Securities Co., Ltd., located in Chengdu, Sichuan, with contact details provided for inquiries [2]. - The legal representative of Huaxi Securities is Yang Jiong Yang, and the contact person is Yang Ru [2]. Group 3: Business Operations - Subscription and redemption services are only available during normal subscription periods and specific open days, with details outlined in the fund's legal documents [3]. - A regular investment plan allows investors to set up automatic deductions for fund purchases, with specific rules governed by Huaxi Securities [3]. Group 4: Fee Structure - Investors may benefit from fee discounts for one-time subscriptions or regular investment plans, subject to the arrangements of Huaxi Securities [4]. - The fund has two classes of shares: Class A, which incurs a subscription fee, and Class C, which does not charge a subscription fee but incurs a service fee [6][7]. Group 5: Redemption Policies - There is no minimum redemption amount, but if a redemption results in a balance of less than one share, the remaining shares must be redeemed [8]. - Redemption fees are applicable and decrease with the holding period of the shares [10]. Group 6: Fund Net Asset Value Disclosure - The fund's net asset value will be disclosed at least weekly during the closed period and no later than the next business day after each open day [11]. Group 7: Additional Information - Investors can access the fund's legal documents, including the fund contract and prospectus, through the company's website or sales institutions for detailed information [12].

华西证券股份有限公司 2026 年面向专业投资者公开发行公司债 券（第二期）在深圳证券交易所上市的公告 根据深圳证券交易所债券上市的有关规定，华西证券股份有限公司 2026 年 面向专业投资者公开发行公司债券（第二期）符合深圳证券交易所债券上市条件， 将于 2026 年 2 月 4 日起在深圳证券交易所上市，并面向专业投资者中的机构投 资者交易，交易方式包括匹配成交、点击成交、询价成交、竞买成交和协商成交。 债券相关要素如下： 华西证券股份有限公司 年 月 日 | 债券名称 | 华西证券股份有限公司 2026 年面向专业投资者公开发 | | --- | --- | | | 行公司债券（第二期） | | 债券简称 | 华股 26 02 | | 债券代码 | 524644 | | 信用评级 | 主体 AAA/债项 AAA | | 评级机构 | 联合资信评估股份有限公司 | | 发行总额（亿元） | 20.00 | | 债券期限 | 454 天 | | 票面年利率（％） | 1.77 | | 利率形式 | 固定利率 | | 付息频率 | 每年付息一次 | | 发行日 | 年 月 日至 年 月 日 2026 1 28 ...

Group 1 - The small nucleic acid drug industry is recommended to focus on three categories: clinical progress type (key targets with Phase III data + beneficiaries of medical insurance), technology platform type (extracellular delivery + multi-target technology companies), and international cooperation type (local companies endorsed by MNCs) to capture dual dividends from new drug launches and data readout windows [1] - Small nucleic acid drugs have become a core track in precision medicine due to their technological breakthroughs and therapeutic differentiation, covering thousands of rare and chronic disease-related targets [1] - The global market for small nucleic acid drugs is expected to grow from $2.7 billion in 2019 to $5.7 billion in 2024, with a CAGR of 16.2%, and projected to reach $20.6 billion by 2029, driven by the increase in chronic diseases and significant drug commercialization [2] Group 2 - The industry is entering a high growth phase, with over 50% of the 19 drugs currently on the market targeting rare diseases, while the proportion of chronic diseases is expected to gradually increase [2] - Key players in the industry include Alnylam and Ionis, which dominate the market with their technological barriers, while local companies like Reebio and Bowang Pharmaceutical are focusing on niche areas [2] - 2025 is anticipated to be a pivotal year for small nucleic acid drugs, with several key drugs expected to achieve significant sales milestones and clinical endpoints [3]

Group 1 - The core viewpoint of the news is that Huaxi Securities experienced a decline in stock price and significant trading activity, with notable financing and margin trading figures reported on February 2 [1] - On February 2, Huaxi Securities' stock fell by 2.28%, with a trading volume of 300 million yuan. The financing buy-in amount was 31.56 million yuan, while the financing repayment was 22.19 million yuan, resulting in a net financing buy of 9.37 million yuan [1] - As of February 2, the total margin trading balance for Huaxi Securities was 1.187 billion yuan, with the financing balance accounting for 5.01% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Huaxi Securities, established on July 13, 2000, and listed on February 5, 2018, primarily engages in brokerage and wealth management, credit business, investment banking, asset management, and investment activities [2] - For the period from January to September 2025, Huaxi Securities reported an operating income of 3.493 billion yuan, representing a year-on-year growth of 56.52%, and a net profit attributable to shareholders of 1.059 billion yuan, with a remarkable year-on-year increase of 316.89% [2] - The company has distributed a total of 1.591 billion yuan in dividends since its A-share listing, with 538 million yuan distributed over the past three years [3]

债券代码：148180 债券简称：23 华股 01 证券简称：华西证券 证券代码：002926 公告编号：2026-004 华西证券股份有限公司 2023年面向专业投资者公开发行公司债券（第一期） 2026年本息兑付暨摘牌公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要内容提示： 债券简称：23 华股 01 债券代码：148180 最后交易日：2026 年 2 月 6 日 债权登记日：2026 年 2 月 6 日 1．发行人：华西证券股份有限公司。 2．债券名称：华西证券股份有限公司 2023 年面向专业投资者公开发行公司 债券（第一期）。 3．债券简称：23 华股 01 1 4．债券代码：148180 债券摘牌日：2026 年 2 月 9 日 本息兑付日：2026 年 2 月 9 日 计息期间：2025 年 2 月 9 日至 2026 年 2 月 8 日 华西证券股份有限公司2023年面向专业投资者公开发行公司债券（第一期） （以下简称："本期债券"）将于2026年2月9日支付2025年2月9日至2026年2月8日 期间的利息并兑付本金。为保证本息兑付 ...

Core Viewpoint - The report from Huaxi Securities highlights a significant drop in gold prices, with a decline of over 9% on January 30, marking the largest single-day drop in 40 years. This decline is attributed to market concerns over the potential shift in Trump's preference for a weaker dollar, which has historically supported gold prices. The long-term outlook for gold remains positive due to structural issues in the US GDP and persistent expectations of interest rate cuts [1]. Supply - Gold supply is projected to increase by 1% year-on-year by 2025, reaching 5,002.3 tons. Producers are focusing on full-price risk exposure with limited interest in hedging. Despite a positive outlook for gold miners in 2025, the market's median expectation for falling gold prices may lead some participants to adopt a more cautious approach [1]. Demand - Total gold demand (excluding OTC and others) is expected to reach 4,999.4 tons in 2025, reflecting an 8% year-on-year increase. Notably, investment demand is projected to surge by 84% to 2,175.3 tons, while demand for gold jewelry is anticipated to decline by 19% to 1,638.0 tons [2]. Jewelry - Global jewelry demand is expected to decline in volume due to rising gold prices, but the value of demand is projected to increase across all markets. This indicates that consumers are willing to spend more on jewelry despite the volume decrease, driven by higher gold prices [3]. Investment - Global gold investment is forecasted to more than double, reaching an impressive $240 billion in 2025. Key drivers include safe-haven demand, geopolitical risks, and expectations of interest rate cuts. The fourth quarter of 2025 is expected to see a historical high in investment demand, with total purchases of ETFs, gold bars, and coins reaching 1,141 tons [4]. Central Banks - Central bank net gold demand is projected to rise to 230 tons in the fourth quarter of 2025, a 6% increase from the previous quarter. Despite a cautious approach due to rising gold prices, central banks' long-term interest in gold remains strong, with total annual demand reaching 863 tons [5]. Industrial - Gold demand in the technology sector is expected to remain stable, with the fourth quarter showing consistent performance. The demand for gold in electronics is driven by the ongoing AI boom, although there are challenges in other areas of the electronics sector due to capacity constraints [6][7]. Investment Recommendations - The ongoing geopolitical tensions and the acceleration of "de-dollarization" trends are expected to sustain central bank and investor demand for gold. Concerns over global debt and monetary policies are likely to benefit gold prices in the long term. The report suggests focusing on gold resource stocks, which are currently undervalued, with specific companies highlighted for potential investment opportunities [8].

登录新浪财经APP 搜索【信披】查看更多考评等级 重要提示 1、景顺长城中证全指农牧渔交易型开放式指数证券投资基金（以下简称"本基金"）的募集已获中国证 监会证监许可[2025]2722号文准予募集注册。 2、本基金是交易型开放式、股票型证券投资基金。 3、本基金的基金管理人为景顺长城基金管理有限公司（以下简称"本公司"），基金托管人为国投证券 股份有限公司，登记机构为中国证券登记结算有限责任公司。 4、本基金的募集对象符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格境 外投资者及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、本基金自2026年2月24日至2026年3月6日进行发售，基金的募集期限不超过3个月，自基金份额开始 发售之日起计算。投资者可选择网上现金认购和网下现金认购2种方式认购本基金。 网上现金认购的日期为2026年2月24日至2026年3月6日，如上海证券交易所对网上现金认购时间做出调 整，基金管理人将做出相应调整并及时公告； 网下现金认购的日期为2026年2月24日至2026年3月6日； 基金管理人可根据基金销售情况在募集期限内适当延长或缩短基金发售时间（包 ...

Core Viewpoint - The performance of listed securities firms in 2025 is expected to be strong, driven by active capital markets and robust growth in brokerage and proprietary trading businesses [1][2]. Group 1: Performance of Major Securities Firms - 21 listed securities firms have disclosed their 2025 performance forecasts, showing overall positive growth in net profits [2]. - CITIC Securities is projected to achieve over 30 billion yuan in net profit, with a revenue of 74.83 billion yuan, marking a 28.75% year-on-year increase [2]. - Guotai Junan expects a net profit between 27.53 billion yuan and 28.01 billion yuan, reflecting a year-on-year growth of 111% to 115% [2]. - Other notable firms include招商证券 with a net profit of 12.3 billion yuan (up 18.43%), and申万宏源 with a projected net profit of 9.1 billion to 10.1 billion yuan (up 74.64% to 93.83%) [2]. Group 2: Performance of Small and Medium-sized Securities Firms - Smaller firms like国联民生 anticipate a net profit of 2.008 billion yuan, representing a significant year-on-year growth of approximately 406% [3]. -天风证券 expects to turn a profit with a net profit forecast of 12.5 million to 18.5 million yuan [3]. - Other small firms such as长江证券 and中原证券 are also expected to see net profit increases exceeding 100% and 50%, respectively [3]. Group 3: Drivers of Growth - The growth in performance is attributed to the active capital market, with wealth management, proprietary trading, and asset management businesses benefiting significantly [3]. - Guotai Haitong noted a substantial increase in income from wealth management and institutional trading due to the rising activity in the domestic capital market [3]. - CITIC Securities reported rapid growth across brokerage, investment banking, and proprietary trading revenues [3]. Group 4: Investment Value of the Sector - The non-bank financial sector has seen a decline of 1.59% as of January 30, but analysts believe that the valuation of securities firms is at a historically low level, enhancing their investment appeal [4]. - The sector is entering a golden window for valuation and performance recovery, driven by favorable policies and an improving market environment [5]. - Analysts suggest focusing on three investment themes: strong comprehensive capabilities of leading firms, firms with significant performance elasticity, and those with strong international business competitiveness [5].

春节时点差异亦会放大阶段性扰动。兴业证券认为，在"晚春"年份，1月资金面波动通常相对较小，但 节前阶段性扰动仍可能出现。2026年春节较晚，预计1月末及2月节前资金面或将出现阶段性波动，央行 的呵护力度仍是市场关注的关键变量。 不惧扰动 跨节资金面压力或总体可控 ◎记者 张欣然 在央行持续通过中期工具投放流动性、短端资金利率保持相对稳定的背景下，市场关注的焦点正逐步转 向春节前后的跨月、跨节资金运行节奏。 多家机构认为，尽管受信贷"开门红"、政府债发行前置及季节性取现需求等因素影响，春节前后资金面 扰动因素有所增加，但在央行呵护下，资金面跨节压力总体仍然可控。 资金面或受季节性扰动 进入春节前后这一关键时间节点，资金面运行的季节性特征开始显现，市场关注重点在于扰动强度及其 演化节奏。 兴业证券研报认为，从历史经验看，春节前两周资金价格多进入季节性收紧窗口，节后则往往迎来边际 宽松。 从波动特征看，春节前后两周，DR007和DR001的波动幅度通常相对有限。春节前两周资金收敛节奏相 对更为明显，但在临近假期的一周，资金价格抬升速度往往放缓，市场对央行操作的敏感度随之提高。 王青表示，进入2月，居民取现需求上升， ...